Mauritius-based C-Care, HCG in partnership

The partnership aims at improving the quality and accessibility of cancer treatment in Mauritius

C-Care (Mauritius), a private healthcare provider in Mauritius, and Healthcare Global Enterprises (HCG) have entered into a strategic partnership. Under the terms of the Memorandum of Understanding (MoU), HCG will offer clinical and outpatient consultation (OPD) services at the C-Care Cancer Center, located within C-Care Darné, in Floréal. These services will be facilitated by HCG doctors specialising in specific areas of oncology.

The partnership focuses on five key areas: cutting-edge clinical services, training and knowledge-sharing, advanced diagnostic services, facilitation of patient referrals, and an unwavering commitment to excellence. HCG will provide oncologists specializing in specific and complex cases of cancer to Mauritian patients, ensuring access to the most advanced care. Patients will benefit from personalised treatments, coupled with international expertise.

C-Care's nuclear medicine staff will receive training from HCG experts to enhance their skills and knowledge, supporting the professional development of the Mauritian teams and improving patient care. Nuclear medicine is a medical specialty that uses the properties of radioactivity for medical purposes.

C-Care patients can be referred to HCG for PET scans, including both conventional and digital PET scans, at preferential rates. The agreement also guarantees patient follow-up and continuity of care. Mauritians requiring advanced cancer treatments that are not available locally will be referred to HCG hospitals in India, ensuring access to comprehensive care options.

Raj Gore, CEO, Healthcare Global Enterprises added, “HCG is delighted to partner with C-Care and extend its clinical services to patients in Mauritius. The MoU represents a shared vision of improving cancer care and making it more accessible to patients in the region. By bringing our expertise through our cutting-edge clinical and OPD services, we are committed to provide personalised, advanced and precise cancer care to the citizens of Mauritius. This collaboration will not only significantly enhance the quality of care available but also provide opportunities for C-Care's medical team to expand their expertise through collaborative training and knowledge exchange.”

Hélène Echevin, CEO, C-Care Group, “The collaboration with HCG underlines our commitment to providing world-class healthcare to our patients. By leveraging HCG's expertise, we aim to improve the quality of cancer care available in Mauritius and ensure that our patients have access to the best possible treatment options. This collaboration will also enable our teams to achieve a high level of quality in all aspects of cancer, even the most complex.”